Analytical Data
-
Gene name
ANTXR2
- Application
-
Alternative Names
CMG-2; CMG2; ISH; JHF; Capillary Morphogenesis Protein 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P58335
-
Expression Region
Gln34~Gly318
-
Molecular Weight
34kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ANTXR2, also known as anthrax toxin receptor 2, is a crucial protein that plays a significant role in cellular activities, particularly in the context of anthrax pathogenesis. It is a member of the tumor necrosis factor receptor superfamily and is implicated in various physiological processes such as cell proliferation, differentiation, and apoptosis. Research on ANTXR2 has gained interest due to its potential involvement in cancer biology, as its expression patterns can be associated with tumor progression and metastasis. Moreover, ANTXR2 serves as a receptor for anthrax toxin, specifically binding to protective antigen and facilitating the entry of lethal factors into host cells. This dual role makes it a target of interest for therapeutic interventions, as blocking this interaction could have implications for anthrax treatment and the development of novel cancer therapies. As such, studies focusing on the structure, function, and signaling pathways of ANTXR2 are essential to understanding its contributions to disease mechanisms. Ongoing research aims to elucidate its roles in various biological contexts, paving the way for potential biotechnological and clinical applications. Understanding ANTXR2 at the molecular level may provide insights into targeted therapies, improving treatment strategies for diseases associated with its dysregulation.
